- Home
- RVYL vs GOVX Comparison
RVYL vs GOVX Comparison
Compare RVYL & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVYL
- GOVX
- Stock Information
- Founded
- RVYL 2007
- GOVX 2001
- Country
- RVYL United States
- GOVX United States
- Employees
- RVYL N/A
- GOVX N/A
- Industry
- RVYL Professional Services
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- RVYL Consumer Discretionary
- GOVX Health Care
- Exchange
- RVYL Nasdaq
- GOVX Nasdaq
- Market Cap
- RVYL 7.3M
- GOVX 7.6M
- IPO Year
- RVYL N/A
- GOVX N/A
- Fundamental
- Price
- RVYL $0.30
- GOVX $0.70
- Analyst Decision
- RVYL Hold
- GOVX Strong Buy
- Analyst Count
- RVYL 1
- GOVX 3
- Target Price
- RVYL N/A
- GOVX $10.67
- AVG Volume (30 Days)
- RVYL 5.6M
- GOVX 686.1K
- Earning Date
- RVYL 08-14-2025
- GOVX 11-11-2025
- Dividend Yield
- RVYL N/A
- GOVX N/A
- EPS Growth
- RVYL N/A
- GOVX N/A
- EPS
- RVYL N/A
- GOVX N/A
- Revenue
- RVYL $48,904,000.00
- GOVX $6,143,044.00
- Revenue This Year
- RVYL $27.50
- GOVX N/A
- Revenue Next Year
- RVYL $35.71
- GOVX N/A
- P/E Ratio
- RVYL N/A
- GOVX N/A
- Revenue Growth
- RVYL N/A
- GOVX 1943.07
- 52 Week Low
- RVYL $0.25
- GOVX $0.43
- 52 Week High
- RVYL $2.35
- GOVX $3.88
- Technical
- Relative Strength Index (RSI)
- RVYL 46.18
- GOVX 44.16
- Support Level
- RVYL $0.27
- GOVX $0.65
- Resistance Level
- RVYL $0.31
- GOVX $0.73
- Average True Range (ATR)
- RVYL 0.02
- GOVX 0.04
- MACD
- RVYL 0.01
- GOVX -0.00
- Stochastic Oscillator
- RVYL 56.67
- GOVX 33.72
About RVYL Ryvyl Inc.
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.